Anti-Müllerian hormone (AMH) declines steadily with age, and a typical ng/mL chart reflects that downward slope from peak values in a woman’s early twenties to near-undetectable levels by menopause. In a large U.S. fertility-center dataset of over 17,000 women, median AMH dropped at a rate of about 0.2 ng/mL per year through age 35, then slowed to roughly 0.1 ng/mL per year afterward. But those clean medians can be misleading if you don’t know what shapes the number, what it actually predicts, and what it doesn’t.
What AMH Measures
AMH is produced by the granulosa cells of small, growing follicles in the ovary. It serves as a proxy for the pool of developing follicles that haven’t yet been recruited for ovulation. Because each of those small follicles secretes a bit of AMH into the bloodstream, a blood test captures a snapshot of how many are in the pipeline at any given moment. A higher AMH generally means a larger pool of growing follicles; a lower AMH means the pool has shrunk.
AMH also plays a biological role beyond being a convenient lab marker. It helps regulate how quickly primordial follicles (the dormant reserve) get activated. Without adequate AMH signaling, the resting pool gets depleted faster. Mouse studies show that when AMH processing is enhanced, ovaries contain significantly more follicles that are dying off (atretic), even though the animals still cycle and reproduce normally. That finding underscores a key theme: AMH reflects the quantity of the follicle pool, not the quality of any individual egg.
Typical AMH Ranges by Age
No single chart applies universally, because reference values depend on the population studied, the assay used, and the clinical setting. Women tested at fertility clinics skew toward lower values than the general population, since many are there precisely because of concerns about ovarian reserve. That said, large studies paint a broadly consistent picture. A study of over 17,000 women at U.S. fertility centers reported a steady decline in both median and mean AMH correlated with advancing age, with the average yearly decrease in median AMH at about 0.2 ng/mL per year through age 35, slowing to about 0.1 ng/mL per year after that. A nationwide Chinese population-based study of healthy women found median values of about 6.2 ng/mL for women aged 20–24, dropping to roughly 3.7 ng/mL by ages 33–36, and about 1.1 ng/mL for women 40 and older. A cohort study of nearly 23,000 women found that median AMH fell below 1.2 ng/mL by age 36, with diminished ovarian reserve present in almost 96% of women by age 45.
A Lebanese cross-sectional study found the decline went from about 5.1 ng/mL in the 20–25 age group down to about 0.7 ng/mL in women over 50, with the steepest per-year drop happening before age 35. The broad ranges reported across these populations are worth noting: in the Chinese study, the 5th-to-95th-percentile range for women aged 25–29 was 1.77 to 13.83 ng/mL. That enormous spread means two healthy 27-year-olds can have AMH values that differ by a factor of seven.
The Decline Is Not a Straight Line
A population-based longitudinal study tracking AMH over time found that the decline follows a sigmoid-shaped curve rather than a simple linear drop. The rate of AMH decrease is relatively low until around age 40, after which it accelerates sharply until levels bottom out near the detection limit around age 55. This matters when you’re interpreting a chart, because the spacing between age brackets isn’t uniform. A 28-year-old and a 32-year-old might be surprisingly close in AMH, while a 40-year-old and a 44-year-old could be worlds apart.
Why Clinicians Order AMH Tests
The most common clinical use of AMH is predicting how a woman will respond to ovarian stimulation during IVF or other assisted reproduction. Among all ovarian reserve tests, AMH is considered the earliest and most sensitive marker. It correlates with the primordial follicle pool, predicts ovarian response to stimulation drugs, and helps clinicians calibrate medication doses. In a systematic review, low AMH cutoffs (roughly 0.1–1.66 ng/mL) predicted poor ovarian response with sensitivities between 44% and 97%. Meanwhile, higher cutoffs (roughly 3.4–5.0 ng/mL) helped flag the risk of ovarian hyperstimulation, a potentially dangerous overreaction to fertility drugs.
A study of Chinese women undergoing IVF found that AMH predicted poor response (three or fewer eggs retrieved), high response (more than 15 eggs), and cycle cancellation with strong accuracy. AMH and antral follicle count together also correlated positively with the number of oocytes retrieved. In practical terms, your AMH level helps your fertility doctor decide how aggressive to be with stimulation and how closely to monitor you.
AMH and Natural Fertility Are Not the Same Thing
This is where the ng/mL chart can seriously mislead people. A low AMH tells you that your pool of growing follicles is smaller than average for your age. It does not tell you that you can’t get pregnant on your own. A systematic review and meta-analysis specifically examining whether AMH predicts spontaneous pregnancy concluded that its predictive value for natural conception is poor, regardless of the woman’s age group. Low AMH was not associated with reduced fertility in the studies analyzed.
One reason for this disconnect is that AMH measures quantity, not quality. You only need one good egg per cycle to conceive, and AMH says nothing about whether any individual egg is chromosomally normal or capable of developing into a healthy embryo. Available tests estimate oocyte numbers but not the most pivotal parameter: oocyte quality. A study comparing women with unexplained infertility to those with male-factor infertility found no significant difference in the proportion with very low AMH (below 0.7 ng/mL), and the odds ratio linking low AMH to infertility was not significant.
That said, the picture has some nuance. One study of women trying to conceive naturally found that pregnancy rates were higher among those with higher AMH: about 78% in the high-AMH group versus 60% in the low-AMH group. The highest pregnancy rate, around 84%, was seen in regularly cycling women with high AMH. But the same study noted enormous variation in time to pregnancy within any given AMH range, and natural conceptions occurred even at very low AMH concentrations. The takeaway is that AMH tilts the odds modestly in the context of natural conception, but it is far from destiny.
Predicting Menopause Timing
Because AMH tracks the shrinking follicle pool, researchers have explored using it to predict when menopause will arrive. AMH does predict time to menopause and outperforms other markers like FSH. In one study of women aged 35–48, those with very low baseline AMH (below 0.20 ng/mL) in the 45–48 age group had a median time to menopause of about 6 years, while those in the 35–39 age group with the same low AMH had roughly 10 years left. Women with AMH above 1.50 ng/mL in the youngest group had more than 13 years until menopause.
However, the precision of these predictions is limited. An individual-patient-data meta-analysis found that when AMH was added to age, the overall predictive accuracy improved only modestly: from 84% with age alone to 86% with age plus AMH. Where AMH added the most value was in predicting early menopause (at or before age 45), boosting accuracy from 52% to 80%. But for the general population, the prediction intervals remain wide enough that telling a specific woman “you will reach menopause at age X” based on her AMH is unreliable. A systematic review echoed this, noting that while AMH consistently predicts the direction of menopause timing, the models don’t handle the extremes well and have wide prediction intervals.
What Can Throw Off Your Number
Several factors can make your AMH result look artificially high or low, which is a problem if you’re comparing it to a standard age-based chart.
Hormonal Contraceptives
Combined oral contraceptive pills suppress AMH by roughly 17–24%, depending on the study. A cross-sectional analysis of over 27,000 women found that pill users had AMH levels about 24% lower than non-users, with similar reductions for vaginal rings and implants. A population study of over 42,000 women reported a 17% reduction with combined oral contraceptives but found no significant suppression from hormonal IUDs. A meta-analysis confirmed the pattern, showing a significant decline in AMH within three months of starting oral contraceptives. The suppression appears to be reversible: AMH rebounds after stopping, but if you’re tested while on the pill, your result will underestimate your actual ovarian reserve.
Body Weight, Smoking, and Ethnicity
Higher BMI is inversely associated with AMH levels regardless of age, race, or smoking status. Current smoking (though not past smoking) has been linked to substantially lower AMH, with one study finding a 44% reduction in current smokers. Smoking also independently accelerates the timeline to menopause. Vitamin D deficiency, which is more common in women of color, may contribute to lower AMH levels, though the mechanistic evidence is still developing. Studies consistently show ethnic and racial differences in AMH values, with Black and Hispanic women tending to have lower levels than white or Asian women after adjusting for age. Whether this reflects genuine differences in follicle pool size, environmental exposures, or genetic variation in the hormone’s signaling pathway remains an open question.
The Assay Problem
Not all AMH tests produce equivalent numbers. Different commercial immunoassays can give meaningfully different results for the same blood sample. One study comparing three assay systems found that converting values between assays using regression equations was potentially highly inaccurate. Another analysis warned against directly converting clinical cutoffs from studies that used one assay to clinical practice using a different one. If your lab reports results in pmol/L rather than ng/mL, the conversion factor is 1 ng/mL = 7.18 pmol/L, but even that simple math doesn’t solve the between-assay variation problem.
This is relevant when you look at an AMH chart online and try to match it to your lab result. The chart may have been generated with a different assay platform than the one your clinic uses. Standardization efforts have improved things over the past decade, but variation persists, and your doctor should interpret your number in the context of the specific assay their lab runs.
When AMH Is Unusually High
While most of the anxiety around AMH focuses on low values, an unusually high number carries clinical meaning too. Polycystic ovary syndrome (PCOS) is associated with elevated AMH because the ovaries contain an excess of small antral follicles, each secreting AMH. A meta-analysis found that an AMH cutoff of about 4.7 ng/mL had roughly 83% sensitivity and 79% specificity for diagnosing PCOS in symptomatic women. Age-specific thresholds may perform better: one study in Chinese women found optimal PCOS cutoffs of 8.16 ng/mL for women in their twenties and 5.89 ng/mL for women in their thirties.
If your AMH chart shows you well above the median for your age, it doesn’t automatically mean PCOS, but it’s worth discussing with your doctor if you also have irregular periods, signs of excess androgens, or difficulty ovulating. Conversely, if you have PCOS, your AMH may look reassuringly high on a standard chart while masking a different set of reproductive challenges entirely.
AMH After Cancer Treatment
Chemotherapy, particularly regimens involving alkylating agents, can drastically reduce AMH levels by damaging the ovarian follicle pool. Following treatment, AMH is often much lower compared to pre-treatment levels, and recovery depends on the specific drugs used, the woman’s age, and her baseline AMH before treatment. Pre-treatment AMH levels predict not just how much damage occurs but how quickly the ovaries bounce back: women with pre-treatment AMH above 2 ng/mL recovered at a rate of about 12% per month after chemotherapy, compared to roughly 3% per month for those starting below 2 ng/mL.
Tracking AMH before, during, and after chemotherapy helps oncologists and reproductive specialists compare the gonadotoxicity of different treatment protocols. Different patterns of AMH recovery allow clinicians to distinguish between more and less ovary-damaging regimens. However, extrapolating a post-treatment AMH level to a specific fertility prediction requires caution, and data on using AMH to estimate time to menopause in cancer survivors are very limited.
One Advantage of AMH Testing
Unlike FSH and estradiol, which fluctuate significantly depending on where you are in your menstrual cycle, AMH stays remarkably stable throughout the cycle. Multiple studies, including a systematic review and meta-analysis, have confirmed that AMH does not show significant variation across cycle days. Prospective studies in normally ovulating women found that any minor fluctuations remained within the range of normal cycle-to-cycle variability. This means you can get your blood drawn for AMH on any day of your cycle, which simplifies scheduling and makes the test more practical than older ovarian reserve markers that required precise timing.
Direct-to-Consumer AMH Tests
A growing number of companies now sell at-home AMH kits directly to consumers, often with marketing that implies the result will tell you how fertile you are. A study evaluating these websites identified two major risks. First, consumers with normal or high results may be falsely reassured and delay trying to conceive, despite age being the single most important factor in fertility. Second, consumers who receive a low result may become needlessly anxious and feel pressured to conceive earlier than planned or pursue unnecessary treatments like IVF or egg freezing.
The problem is that these tests strip away the clinical context that makes AMH useful. Without knowing your age, menstrual history, contraceptive use, BMI, or reproductive goals, a raw ng/mL number on a color-coded chart can do more harm than good. An AMH of 1.0 ng/mL means something very different in a 28-year-old with regular cycles than in a 42-year-old planning IVF.
AMH in Males and Children
AMH isn’t exclusively a female fertility marker. In boys, AMH is produced by Sertoli cells in the testes and serves as a biomarker of testicular function from birth through the early stages of puberty. It’s especially useful in evaluating boys with undescended testes (cryptorchidism): when gonads can’t be felt on physical exam, a measurable AMH in the blood confirms that testicular tissue exists somewhere. In boys with cryptorchidism, AMH levels reflect the mass of functional Sertoli cells, running lower in bilateral cases than unilateral ones. After puberty, male AMH drops sharply as testosterone rises and Sertoli cells mature, so the clinical window for using AMH as a pediatric testicular marker is limited to childhood.
This entirely separate role for AMH in males is worth knowing if you encounter AMH reference ranges that seem wildly different from fertility-clinic charts. A prepubertal boy can have AMH levels many times higher than an adult woman in her twenties, because the hormone is doing a completely different job in a completely different organ system.